Erbitux (cetuximab) is a monoclonal antibody targeting the EGFR receptor, used in the treatment of colorectal cancer and head and neck cancers. SGK does not exclude this drug entirely, but reimburses it only for patients meeting the strict conditions defined in the Health Implementation Communiqué (SUT). Once those conditions are exceeded — for example, continuing the drug despite disease progression, or using it at a different treatment line — SGK refuses payment and patients are forced to pursue a legal remedy.
What Is Erbitux (Cetuximab)?
Cetuximab is a targeted therapy that binds to EGFR (epidermal growth factor receptor) on the surface of cancer cells, blocking the cell-proliferation signal. Its main licensed indications in Turkey are:
- RAS wild-type metastatic colorectal cancer, combined with FOLFOX or FOLFIRI chemotherapy regimens
- Squamous cell head and neck cancer, combined with platinum-based chemotherapy or radiotherapy
Under What Conditions Does SGK Cover Erbitux?
According to SUT, the main conditions for Erbitux to be reimbursed are:
- The patient has not previously received cetuximab or another anti-EGFR therapy,
- An ECOG performance status of 0-1 (the patient's general condition is suitable for treatment),
- In metastatic colorectal cancer, the RAS gene is shown to be wild-type (non-mutated),
- These conditions are documented by a health board report including at least one medical oncology specialist.
When these conditions are met, Erbitux is covered by SGK. However, SUT also clearly sets a limit: if disease progression is observed during treatment, or the accompanying chemotherapy regimen is changed, Erbitux (or another anti-EGFR therapy) is no longer within the reimbursement scope. The same result follows in head and neck cancer if the required combination with radiotherapy or chemotherapy is not met. In practice, most disputes arise at these boundary points — situations where the drug is alleged to fall outside the "window" defined in SUT.
Erbitux 2026 Price
Based on current data, a 100 mg vial of Erbitux costs approximately 9,200-9,300 TL; the larger 500 mg vial is priced proportionally higher based on the body-surface-area dose calculation. Because treatment is administered weekly, the total monthly cost can exceed one hundred thousand TL depending on the dose used. It is advisable to confirm the current price with a pharmacy or hospital.
Legal Process When SGK Refuses Payment
Two different scenarios may arise in disputes concerning Erbitux:
A) SGK refuses payment despite the SUT conditions being met: In this case SGK's refusal is unlawful and an action may be filed directly for its annulment.
B) Use outside the conditions defined in SUT (off-label): For example, if it is medically determined that the drug must be continued after progression, this use is treated as "off-label" and the following process applies:
- [Application to TİTCK for off-label use approval](/en/ictihat/endikasyon-disi-ilac-belgeler): The treating physician applies, documenting that the drug is necessary for the patient's treatment and that no alternative exists.
- Written application to SGK: Submitted to the Provincial Directorate of SGK together with the approval and physician's reports.
- Filing a case: If SGK refuses or fails to respond, a case is filed before the labour court or administrative court depending on the patient's insurance status.
- Request for an interim injunction: Requested from the court so that the drug is supplied without interruption while the case is pending.
- Expert examination: The court has oncology specialists assess whether the drug is medically necessary for the disease.
Required Documents
| Document | Description |
|---|---|
| Health board report | States RAS mutation status, ECOG score, and treatment history |
| Genetic test result | Proof of RAS wild-type / mutation status |
| Pathology and discharge reports | Type and stage of the disease |
| TİTCK application/approval document | Required if off-label use is involved |
| SGK refusal letter or application record | Proof of the pre-litigation application |
| Invoices | If the drug cost was paid out of pocket |
Duration of Proceedings
Cases based on an unjustified refusal within SUT conditions can proceed relatively quickly, while cases alleging off-label use typically take an average of 6 to 18 months due to the expert examination process. If the request for an interim injunction is granted, treatment can continue without interruption while the case is pending.
Frequently Asked Questions
Does SGK always cover Erbitux?
No, it is covered only for patients meeting the RAS wild-type, performance score, and treatment-line conditions defined in SUT.
Will SGK pay if Erbitux is continued after disease progression?
Under SUT, use after progression falls outside the reimbursement scope; in that case the cost can be claimed through litigation.
Can Erbitux be used in patients with a RAS mutation?
That is a medical decision for the physician; SGK's reimbursement, however, is conditional on the RAS wild-type requirement.
Under what conditions is Erbitux covered in head and neck cancer?
Both a combination with radiotherapy or a specific chemotherapy regimen and a health board report must be satisfied together.
Is an application to SGK mandatory before filing a case?
Yes, a case cannot be filed without a prior written application to SGK and a refusal response.
Frequently Searched Questions
How Should a Petition for an Erbitux SGK Application Be Prepared?
The petition should include the genetic test result confirming RAS wild-type status, a health board report stating the ECOG performance score, treatment history showing the patient has not previously received anti-EGFR therapy, and SGK's refusal letter.
Where Is the Cost of Erbitux Obtained From?
For patients meeting the SUT conditions (RAS wild-type, ECOG 0-1, first use), Erbitux is supplied directly through hospital pharmacies under SGK's protocol. Where use falls outside those conditions — such as continuing after disease progression — the drug may need to be purchased out of pocket from a private pharmacy while the case is pending.
Can the Amount Paid for Erbitux Be Reclaimed?
Yes. Erbitux costs paid out of pocket due to an unjustified refusal despite meeting SUT conditions can be reclaimed through litigation supported by invoices; the claim is subject to the 5-year limitation period under Article 97 of Law No. 5510.
Why Does SGK Refuse Erbitux Requests?
The most common grounds are the presence of a RAS mutation, requesting to continue the drug despite disease progression, an ECOG performance score outside the 0-1 range, and the patient having previously received another anti-EGFR therapy.
Which Court Hears an Erbitux Case?
Insured persons under SSK or Bağ-Kur file their case before the labour court, while civil servants and retired civil servants within the scope of Article 4/c of Law No. 5510 file before the administrative court.
Related Reading
Av. Barış Ürün
Avukat — Ankara Barosu